The empirical combination of vancomycin and a β-lactam for staphylococcal bacteremia

Clinical Infectious Diseases

Volumn 57, Issue 12, 2013, Pages 1760-1765

  McConeghy, Kevin W ^a   Bleasdale, Susan C ^b   Rodvold, Keith A ^a,b  

^a Department of Pharmacy Practice   (France)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

empirical therapy; MRSA; MSSA; nafcillin; vancomycin

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFAZOLIN; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; LINEZOLID; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; VANCOMYCIN; WARFARIN;

ADD ON THERAPY; ANAPHYLAXIS; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; CATHETER INFECTION; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ENDOCARDITIS; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INTERSTITIAL NEPHRITIS; LEUKOPENIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; META ANALYSIS (TOPIC); METASTASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; PREOPERATIVE CARE; PRIORITY JOURNAL; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EMPIRICAL THERAPY; MRSA; MSSA; NAFCILLIN; VANCOMYCIN;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; COHORT STUDIES; DRUG THERAPY, COMBINATION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84890084767     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit560     Document Type: Article

References (45)

1. Deresinski S. Principles of antibiotic therapy in severe infections: Optimizing the therapuetic approach by use of laboratory and clinical data. Clin Infect Dis 2007; 45:S177-83
2. Bartlett JG. A call to arms: The imperative for antimicrobial stewardship. Clin Infect Dis 2011; 53(S1):S4-7
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H,Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17
4. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322-32
5. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23
6. Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical- Therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731-3
7. Mongkolrattanothai K, Aldag JC, Mankin P, Gray BM. Epidemiology of community-onset Staphylococcus aureus infections in pediatric patients: An experience at a children's hospital in central Illinois. BMC Infect Dis 2009; 9:112
8. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau- Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005; 45:311-20
9. Tattevin P, Schwartz BS, Graber CJ, et al. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to communityassociated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2012; 55:781-8
10. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epid 2013; 34:1-14
11. Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control 2008; 36:118-22
12. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med 2008; 121:310-5
13. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:1-38
14. Gómez J, García-Vázquez E, Baños R, et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: The role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007; 26:239-45
15. Marchaim D, Kaye KS, Fowler VG, et al. Case-control study to identify factors associated with mortality among patients with methicillinresistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2010; 16:747-52
16. Rodríguez-Baño J, Millán AB, Domínguez MA, et al. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. J Infect 2009; 58:131-7
17. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin- resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-74
18. Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2010; 65:2658-65
19. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9
20. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38:7-14
21. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis- dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6
22. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192-7
23. Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11:279-86
24. Chan KE, Warren HS, Thadhani RI, et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23:1551-9
25. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25:181-5
26. Lee S, Choe PG, Song KH, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother 2011; 55:5122-6
27. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011; 17:1581-6
28. Geiger K, Brown J. Rapid testing for methicillin-resistant Staphylococcus aureus: Implications for antimicrobial stewardship. Am J Health Syst Pharm 2013; 70:335-42
29. Parta M, Goebel M, Thomas J, Matloobi M, Stager C, Musher DM. Impact of an assay that enables rapid determination of Staphylococcus species and their drug susceptibility on the treatment of patients with positive blood culture results. Infect Control Hosp Epidemiol 2010; 31:1043-8
30. Bernardo K, Pakulat N, Macht M, et al. Identification and discrimination of Staphylococcus aureus strains using matrix-assisted laser desorption/ ionization-time of flight mass spectrometry. Proteomics 2002; 2:747-53
31. Joukhadar C, Pillai S,Wennersten C, Moellering RC Jr, Eliopoulos GM. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:773-7
32. Rudolf AH, Price EV. Penicillin reactions among patients in venereal disease clinics: A national survey. JAMA 1973; 223:499-501
33. Petz LD. Immunologic reactions of humans to cephalosporins. Postgrad Med J 1971; 47(suppl):64-9
34. Aldeyab MA, Monnet DL, López-Lozano JM, et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: A time-series analysis. J Antimicrob Chemother 2008; 62:593-600
35. Kaier K, Hagist C, Frank U, Conrad A, Meyer E. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30:346-53
36. Sieradzki K, Wu SW, Tomasz A. Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus. Microb Drug Resist 1999; 5:253-7
37. Adhikari RP, Scales GC, Kobayashi K, Smith JM, Berger-Bächi B, Cook GM. Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus. J Antimicrob Chemother 2004; 54:360-3
38. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: Exploring the "seesaw effect." Antimicrob Agents Chemother 2013; 57:2664-8
39. Fowler VG, Boucher HW, Corey R, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65
40. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48:203-12
41. Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillinresistant Staphylococcus aureus: Complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 2011; 14:631-9
42. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. Coopting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc 2008; 130:9212-3
43. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50
44. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2089-96
45. Boyd N, Nailor MD. Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2011; 31:1073-84